Cierra N. Sharp

Cierra N. Sharp

May 23, 2016

Group 6 Copy 46
0
    Please wait...

    About This Project

    A major dose-limiting toxicity of some chemotherapeutics (like cisplatin) is nephrotoxicity, leading to acute kidney injury (AKI) in 30% of patients. The aim of my project is to develop a mouse model that recapitulates the dosing regimen humans receive in order to develop and test novel renoprotective agents. This is important as there are no therapeutic interventions for cisplatin-induced AKI, and no long-term studies on kidney function have been performed in mice treated with cisplatin.

    Blast off!

    Browse Other Projects on Experiment

    Related Projects

    Genetically Engineering Bacteria to Measure and Sequester Fluoride to Clean Our Waters

    We are the ECHHS iGem team! Last year, we successfully tested a plasmid that identifies fluoride bioswitches...

    How do chimpanzees adapt to a savanna woodland in Tanzania?

    75% of Tanzania’s chimpanzees live in open “savanna” woodlands. Considered a marginal habitat due to low food...

    Backer Badge Funded